BioSig Advances its PURE™ System Commercial Launch to Medical Centers Nationwide
May 26 2022 - 8:08AM
-
Commercial pipeline to include 30 advanced
leads at Medical Centers of Excellence
- Company’s development and operational infrastructure
will be on track to support anticipated sales growth following
commercial rollout on July 1, 2022
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company advancing
electrophysiology workflow by delivering greater intracardiac
signal fidelity through its proprietary signal processing platform,
today announced the rollout of the Company’s national commercial
launch campaign.
Under the leadership of its Chief Commercial Officer Gray
Fleming, BioSig has implemented several important initiatives to
accelerate the transition from its limited market release to a
national launch of its PURE EP(TM) System. The Company currently
has over 30 qualified leads ahead of its official commercial
kick-off, expected to commence on July 1, 2022. The PURE EP(TM) is
an FDA 510(k) cleared non-invasive class II device that aims to
drive procedural efficiency and efficacy in cardiac
electrophysiology. To date, more than 73
physicians have completed over 2,200 patient cases
with the PURE EP(TM) System.
Commercial strategy highlights include:
- Business agreement with Summit Blue Capital to implement a
leasing and finance program for the PURE EP(TM) System. The
agreement aims to expedite the pathway to purchase and increase the
of scope PURE EP(TM) adopters across the U.S.
- Streamlined product evaluations from 180-360 days to 60 days
with a succinct clinical and economic value proposition that
showcases the advantages of the technology and accelerates
adoption.
- Strengthened management, commercial, clinical, and marketing
teams under the leadership of Gray Fleming, Chief Commercial
Officer, who spent 18 years with St. Jude Medical/Abbott.
- Restructured clinical support and installation teams in
preparation for increased commercial activity. The Company’s new
commercial structure includes national account directors covering
five regions in the United States to support product evaluations
and the rapid transformation of qualified leads into sales.
- Implemented an effective CRM system and pipeline management
system to support sales opportunities and streamline data and
customer engagements.
- Company to implement new brand strategy and marketing programs
to reflect business growth and evolution. These efforts include an
updated website and new visual content and branding.
“As a Company we have worked tirelessly to reach this point to
commercially roll out our PURE(TM) System nationwide. We have
put the right people in place and have executed on a strategy to
see this come to fruition. We believe July 2022 will be a major
milestone for our Company and we look forward to collaborating with
our new medical centers that recognize the invaluable benefits of
Pure EP(TM) for their patients,” commented Kenneth L. Londoner,
Chairman and CEO of BioSig Technologies, Inc.
Clinical data acquired by the PURE EP(TM) System in a
multi-center study at centers of excellence including Texas Cardiac
Arrhythmia Institute at St. David’s Medical Center and Mayo Clinic
was recently published in the Journal of Cardiovascular
Electrophysiology and is available electronically with open access
via the Wiley Online Library. Study results showed 93%
consensus across the blinded reviewers with a 75% overall
improvement in intracardiac signal quality and confidence in
interpreting PURE EP™ signals over conventional sources.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company's first product, PURE EP™ System, is a computerized
system intended for acquiring, digitizing, amplifying, filtering,
measuring and calculating, displaying, recording, and storing
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements This press
release contains "forward-looking statements." Such statements may
be preceded by the words "intends," "may," "will," "plans,"
"expects," "anticipates," "projects," "predicts," "estimates,"
"aims," "believes," "hopes," "potential" or similar words.
Forward-looking statements are not guarantees of future
performance, are based on certain assumptions, and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company's control and cannot be predicted or
quantified, and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social, and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's filings
with the Securities and Exchange Commission (SEC), including the
Company's Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC's website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events, or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2024 to May 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From May 2023 to May 2024